SILENCE THER. (SLN)

 

SLN Share PerformanceMore

52 week high149.75 15/08/17
52 week low71.90 03/05/17
52 week change 26.50 (22.75%)
4 week volume1,546,922 24/07/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Replacement - Holding(s) in Company

RNS Number: 3319O Silence Therapeutics PLC 17 August 2017 Replacement related to RNS #31770 - title changed, all other details remain the same. TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the un...

Director/PDMR Shareholding

RNS Number: 3177O Silence Therapeutics PLC 17 August 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Silence Thera...

Two further US patents to be granted

RNS Number: 9797N Silence Therapeutics PLC 15 August 2017 Two further US patents to be granted 15 August 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announcesthat theUS Patentand Trade Ma...

Director Deals - Silence Therapeutics PLC (SLN)

Alistair Gray, Non Executive Director, bought 3,848 shares in the company on the 2nd August 2017 at a price of 129.75p. Th...

Director/PDMR Shareholding

RNS Number: 9678M Silence Therapeutics PLC 03 August 2017 Director/PDMR Shareholding 3 August 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it was advised on 2 August that on ...

Director Deals - Silence Therapeutics PLC (SLN)

Dr Andrew Richards, Non Executive Director, bought 7,000 shares in the company on the 31st July 2017 at a price of 146.88...

Director/PDMR Shareholding

RNS Number: 5865M Silence Therapeutics PLC 31 July 2017 Director/PDMR Shareholding 31 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it was advised on 31 July that on that day...

Silence Therapeutics updates on expansion of its patent estate

Silence Therapeutics announced a further step in the expansion of its chemical modification patent estate. Silence said the U...

Fundamental DataMore

EPS-12.1
Dividend yield0 %

Equity Research (SLN)

edison investment research
Silence Therapeutics plc
13/04/2017
Edison Investment Research is terminating coverage on Silence Therapeutics (SLN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should...

Latest discussion posts More

  • Re: Slow decline.

    Hi, Totally agree and I am not sure why apart from just general lack of interest. The attached might help cheer you up a ...
    27-Apr-2017
    tallyfox
  • Slow decline.

    Feels like death by a thousand cuts at the moment. What's it going to take to reverse this decline?
    27-Apr-2017
    rikid

Users' HoldingsMore

Users who hold SILENCE THER. also hold..
LLOYDS GRP.33%
BP23%
BARCLAYS19%
ROYAL BANK SCOT19%
TESCO19%

Codes & Symbols

ISINGB00B9GTXM62
SymbolsSLN, LSE:SLN, SLN.L, SLN:LN, LON:SLN, XLON:SLN